Oki Electric Industry Co., Ltd.

Terumo Kabushiki Kaisha

Taisho Pharmaceutical Co., Ltd.

Terumo Corporation

Fujifilm Healthcare Corporation

Keiko Takahashi

Toshio Wakabayashi

Youichi Yamada

Masakazu Sato

Katsuo Hatayama

Yutaka Kawashima

Akira Manaka

Tadashi Nakamura

Akihiko Fujisawa

Keisuke Yamakawa

Makoto Morito

Yukio Tabei

Yasushi Suwabe

Masao Takeuchi

Hajime Katayama

An X-ray tomosynthesis apparatus accurately extracts a region of a small high absorber in a subject on 2D measurement projection data. When pieces of the 2D measurement projection data for each of a plurality of projection angles are arranged in a projection angle direction, the 2D measurement projection data is shifted in a 2D plane so that part or all of a range of a high absorber region included in the 2D measurement projection data overlaps at least a range of the high absorber region included in 2D measurement projection data at an adjacent projection angle in an in-plane direction of the 2D plane. The 2D measurement projection data for each of the plurality of projection angles after shifting is arranged in the projection angle direction to obtain 3D measurement projection data, and a 3D region is obtained from a first start point by a region expansion process.

X-ray tomosynthesis apparatus, image processing apparatus, and program

Thiazoline derivatives

A thiazoline derivative represented by the formula: ##STR1## [wherein R.sup.1 is cyano, carbamoyl, thiocarbamoyl, morpholinothiocarbonyl, alkylthioimidoyl, amidino, substituted amidino or imidazolin-2-yl, R.sup.2 is alkyl or aralkyl, R.sup.3 is hydrogen or alkyl, R.sup.4 is hydroxyl, alkoxy, substituted alkoxy or amino, l is an integer of 1 to 5] and salts thereof have fibrinogen receptor antagonism and cell adhesion factor antagonism, and are useful as therapeutic agents for ischemic diseases and atherosclerosis diseases, and metastasis inhibitory agents of tumors.

In a speech recognition system which performs a frequency analysis of speech input and determines its spoken interval, a time-normalized pattern (matching pattern) is prepared for use in similarity calculations. In the time-normalization, the time axis is segmented in such a manner as to cancel the effects of differences in the length of syllables in the input speech. With such normalization, it is possible to achieve high performance in linear matching of the input speech pattern against reference patterns using simple processing and a small memory space even when there are variations in the speaking rate.

Speech recognition system in which voiced intervals are broken into

In a speech recognition system using normalized spectrum matching, a second feature pattern is calculated and compared with reference patterns. The similarity obtained as a result of the comparison is used to determine overall similarity, from which the recognition is made. The second feature pattern can be a spectrum variation pattern, a level decrease pattern, or a spectrum relative value pattern.

Speech recognition system which avoids ambiguity when matching frequency

In a speech recognition system for effecting substantially linear matching, a start point of an input speech pattern is detected to start counting the frames of the input speech pattern for updating a speech frame number. Each time the speech frame number is updated, a plurality of frame numbers of reference templates are generated in substantially a linear relationship to the frame number, thus providing a plurality of matching paths between each of the reference templates and the input speech pattern. The distance between the input pattern data and the reference template data between the corresponding frames specified by each matching path is calculated each time the speech frame number is updated. An accumulated value of the distances along a matching path from the start point of the input speech until a desired speech frame is regarded as a dissimilarity, and the dissimilarity corresponding to each matching path in each reference template is calculated each time the speech frame is updated. The number of the reference template which gives a minimum dissimilarity is detected and stored. At the time of confirming an end of the input speech, the number of the reference template with the minimum dissimilarity is determined to be the recognized result of input speech.

Apparatus and method for recognizing speech

In a speech-recognition system in which time-series patterns of characteristic quantities are extracted from an input utterance within a voiced interval, the local-peak patterns, which are the results obtained by stably extracting the characteristics of the steady vowel portions, and the consonantal patterns, which are the results obtained by stably extracting the characteristics of the consonantal portions, are recognized and identified. This makes it possible to perform accurate and stable speech-recognition including also the characteristics of the consonants.

Speech recognition system wherein the consonantal characteristics of

A method of treating or preventing hyperlipemia by administering ethanolamine derivatives. As preferable ethanolamine derivatives are mentioned N-(9,12,15,-octadecatrienoyl)-2-aminoethyl nicotinate, N-(5,8,11,14,17-eicosapentaenoyl)-2-aminoethyl nicotinate and the like. Hyperlipemia is effectively prevented or treated by administering 300-2000 mg per day of said ethanolamine derivative for adults.

Method of treating hyperlipemia

1-substituted 5-fluorouracil useful for inhibiting the aggregation of

Alkanolamine derivatives and platelet aggregation inhibitors containing the same as an active ingredient are disclosed. The alkanolamine derivatives are novel compounds which possess potent platelet aggregation inhibitory activities and effective in preventing diseases such as thrombosis. As typical compounds are mentioned N-5,8,11,14,17-eicosapentaenoyl-2-aminoethanol, N-nicotinoyl-2-aminoethyl-5,8,11,14,17-eicosapentaenoate, N-ethyl-N-5,8,11,14,17-eicosapentaenoyl-2-aminoethanol, N-butyl-N-5,8,11,14,17-eicosapentaenoyl-2-aminoethanol, N-5,8,11,14,17-3-aminopropylnicotinate, (N-ethyl-N-nicotinoyl-2-aminoethyl)-5,8,11,14,17-eicosapentaenoate and the like.

Growing community of inventors

Tokyo, Japan

Keiko Takahashi